ValiRx PLC (GB:VAL)
LSE:VAL
Top Page
ValiRx plc
(LSE:VAL)
Select Model
Select Model
Rating:41Neutral
Price Target:
0.37 p
▼(-8.00% Downside)
Action:ReiteratedDate:12/10/25
ValiRx plc's overall stock score is primarily impacted by its challenging financial performance, characterized by significant losses and reliance on external financing. The technical analysis suggests a bearish trend, with some potential for upward movement. The valuation is unattractive due to a negative P/E ratio and lack of dividend yield.
Positive Factors
Strong equity position
A high equity ratio provides a durable capital buffer to support long development cycles and absorb setbacks. That equity strength reduces near-term insolvency risk, making the company a more stable partner for collaborators and better positioned to pursue clinical milestones before raising costly capital.
Negative Factors
Persistent unprofitability
Sustained net losses and negative margins undermine internal capital generation, forcing repeated external funding. Over the medium term this can dilute shareholders, constrain strategic freedom, and pressure management to prioritize short-term cash raises over optimal long-term R&D decisions.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong equity position
A high equity ratio provides a durable capital buffer to support long development cycles and absorb setbacks. That equity strength reduces near-term insolvency risk, making the company a more stable partner for collaborators and better positioned to pursue clinical milestones before raising costly capital.
Read all positive factors
ValiRx plc (VAL) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£2.19M
Dividend YieldN/A
Average Volume (3M)1.10M
Price to Earnings (P/E)―
Beta (1Y)0.60
Revenue Growth418.49%
EPS Growth27.86%
CountryUK
Employees16
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding742,801,100
10 Day Avg. Volume510,641
30 Day Avg. Volume1,099,814
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.24
Price to Sales (P/S)20.52
P/FCF Ratio-0.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ValiRx plc Business Overview & Revenue Model
Company Description
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a small molecule that has completed Phase I/II trials ...
How the Company Makes Money
ValiRx generates revenue primarily through the development and commercialization of its therapeutic candidates. The company's revenue model includes potential licensing agreements, partnerships with larger pharmaceutical companies, and grants for ...
ValiRx plc Financial Statement Overview
Summary
Income Statement
20
Very Negative
Balance Sheet
40
Negative
Cash Flow
30
Negative
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2020 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 49.77K | 9.60K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -217.22K | -246.04K | -224.27K | -228.79K | -229.50K |
| EBITDA | -1.86M | -2.04M | -2.37M | -1.45M | -1.31M |
| Net Income | -1.92M | -2.04M | -2.41M | -1.55M | -1.47M |
Balance Sheet | |||||
| Total Assets | 4.26M | 3.13M | 3.98M | 3.52M | 4.94M |
| Cash, Cash Equivalents and Short-Term Investments | 1.56M | 174.68K | 1.14M | 593.67K | 1.85M |
| Total Debt | 11.86K | 22.07K | 37.71K | 58.72K | 71.06K |
| Total Liabilities | 346.41K | 226.51K | 149.65K | 109.56K | 182.40K |
| Stockholders Equity | 4.32M | 3.22M | 4.05M | 3.60M | 4.91M |
Cash Flow | |||||
| Free Cash Flow | -1.62M | -2.08M | -1.71M | -1.26M | -2.00M |
| Operating Cash Flow | -1.58M | -1.77M | -1.71M | -1.26M | -1.91M |
| Investing Cash Flow | -38.16K | -306.18K | 0.00 | 0.00 | -91.29K |
| Financing Cash Flow | 3.00M | 1.12M | 2.26M | 7.34K | 3.85M |
ValiRx plc Technical Analysis
Negative
0.40
Price Trends
0.34
Negative
0.33
Negative
0.45
Negative
Market Momentum
>-0.01
Positive
40.83
Neutral
12.50
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:VAL, the sentiment is Negative. The current price of 0.4 is above the 20-day moving average (MA) of 0.32, above the 50-day MA of 0.34, and below the 200-day MA of 0.45, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 40.83 is Neutral, neither overbought nor oversold. The STOCH value of 12.50 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:VAL.
ValiRx plc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | £119.34M | -4.45 | 90.29% | ― | ― | -94.12% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | £4.41M | -0.88 | -53.79% | ― | ― | 85.56% | |
47 Neutral | £61.43M | -0.27 | -3931.14% | ― | ― | ― | |
46 Neutral | £23.88M | -3.00 | 3817.30% | ― | ― | ― | |
44 Neutral | £21.40M | -3.13 | -202.14% | ― | ― | 23.76% | |
41 Neutral | £2.19M | ― | ― | ― | 418.49% | 27.86% |
* Healthcare Sector Average
GB:VAL
ValiRx plc
0.31
-0.26
-46.09%
GB:TCF
Evgen Pharma
0.21
-0.02
-6.82%
GB:IMM
ImmuPharma
4.75
1.56
48.90%
GB:SAR
Sareum Holdings
15.50
3.50
29.17%
GB:SCLP
Scancell Holdings
11.25
3.00
36.36%
GB:HEMO
HemoGenyx Pharmaceuticals Plc
956.00
764.75
399.87%
ValiRx plc Corporate Events
Private Placements and FinancingRegulatory Filings and Compliance
ValiRx Issues 80,000 New Shares Following Warrant Exercise
Neutral
Jan 19, 2026
ValiRx plc has received notification for the exercise of warrants over 80,000 ordinary shares at an exercise price of 0.5 pence per share, raising gross proceeds of £400 for the company. The new shares will be admitted to trading on AIM aroun...
Business Operations and StrategyPrivate Placements and Financing
ValiRx Strikes RNA Helicase Deal with McGill and IRICoR Under Asset-Focused Funding Model
Positive
Jan 9, 2026
ValiRx has signed a nine‑month evaluation and material transfer agreement with McGill University and Canadian non-profit IRICoR to assess a second-generation, orally available RNA helicase inhibitor, with its subsidiary Inaphaea Biolabs resp...
Business Operations and StrategyPrivate Placements and Financing
ValiRx Strikes RNA Helicase Inhibitor Deal with McGill and IRICoR to Drive Asset-Level Growth
Positive
Jan 9, 2026
ValiRx has entered into a nine‑month Evaluation and Material Transfer Agreement with McGill University and IRICoR to assess a second‑generation, orally available RNA helicase inhibitor, with its subsidiary Inaphaea Biolabs responsible ...
Private Placements and FinancingShareholder Meetings
ValiRx Advances with New Equity and Warrant Issuance Post-General Meeting
Positive
Nov 20, 2025
ValiRx plc announced the successful passing of all resolutions at its recent General Meeting, paving the way for the issuance of new equity and warrants as part of its fundraising efforts. The company plans to admit 256,067,800 new shares to tradi...
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
ValiRx PLC Announces Fundraising to Boost Cancer and Women’s Health Research
Positive
Nov 4, 2025
ValiRx PLC has announced the posting of a circular and notice for a General Meeting to discuss a fundraising initiative aimed at raising approximately £902,000. The funds will support research and development efforts, including the preclinica...
Business Operations and StrategyPrivate Placements and Financing
ValiRx PLC Raises £902,000 Through Successful Fundraising
Positive
Nov 4, 2025
ValiRx PLC has successfully raised approximately £902,000 through its WRAP Retail Offer and other fundraising activities, issuing new ordinary shares at a price of 0.25 pence per share. This capital injection is expected to support the compan...
Business Operations and StrategyPrivate Placements and Financing
ValiRx Plc Raises £902,000 Through Successful WRAP Retail Offer
Positive
Nov 4, 2025
ValiRx Plc announced the successful completion of its WRAP Retail Offer, raising approximately £152,000 through the issuance of new ordinary shares. Combined with previous fundraising efforts, the company has secured a total of £902,000....
Business Operations and StrategyPrivate Placements and Financing
ValiRx Plc Launches £300,000 Retail Offer to Boost Cancer Therapeutics Development
Positive
Oct 30, 2025
ValiRx Plc has announced a retail offer via the Winterflood Retail Access Platform to raise up to £300,000 through the issuance of new ordinary shares and warrants. This initiative is part of a broader fundraising effort, where the company ha...
Business Operations and StrategyPrivate Placements and Financing
ValiRx PLC Launches £1.05 Million Fundraising to Boost Cancer and Women’s Health Initiatives
Neutral
Oct 30, 2025
ValiRx PLC has announced a fundraising initiative to raise up to £1,050,000 through a combination of firm and conditional placings, a WRAP Retail Offer, and direct subscriptions by company directors. The initiative, which includes the issuanc...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.